Your browser is no longer supported. Please, upgrade your browser.
Settings
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-1.70 Insider Own0.80% Shs Outstand151.65M Perf Week-2.70%
Market Cap8.52B Forward P/E175.11 EPS next Y0.32 Insider Trans-18.89% Shs Float150.70M Perf Month9.94%
Income-256.70M PEG- EPS next Q0.04 Inst Own98.00% Short Float4.19% Perf Quarter20.31%
Sales695.30M P/S12.26 EPS this Y-635.70% Inst Trans0.13% Short Ratio5.27 Perf Half Y22.49%
Book/sh7.98 P/B7.04 EPS next Y260.00% ROA-14.40% Target Price65.27 Perf Year-23.73%
Cash/sh3.62 P/C15.52 EPS next 5Y- ROE-20.40% 52W Range27.14 - 80.71 Perf YTD-29.19%
Dividend- P/FCF- EPS past 5Y-26.20% ROI-13.70% 52W High-30.21% Beta2.16
Dividend %- Quick Ratio4.00 Sales past 5Y27.50% Gross Margin81.00% 52W Low107.55% ATR2.04
Employees1500 Current Ratio4.20 Sales Q/Q18.00% Oper. Margin-36.30% RSI (14)53.32 Volatility3.73% 3.35%
OptionableYes Debt/Eq0.24 EPS Q/Q23.70% Profit Margin-36.90% Rel Volume0.38 Prev Close56.21
ShortableYes LT Debt/Eq0.23 EarningsNov 02 BMO Payout- Avg Volume1.20M Price56.33
Recom2.20 SMA20-2.34% SMA508.38% SMA20026.39% Volume224,789 Change0.21%
Oct-21-16Upgrade JP Morgan Neutral → Overweight
Oct-21-16Reiterated Leerink Partners Outperform $57 → $70
Oct-21-16Reiterated Jefferies Buy $62 → $70
Oct-04-16Resumed Leerink Partners Outperform $57
Jan-21-16Reiterated Leerink Partners Outperform $84 → $58
Jan-21-16Downgrade Morgan Stanley Overweight → Underweight
Jan-21-16Downgrade JP Morgan Overweight → Neutral
Oct-07-15Reiterated Barclays Overweight $77 → $79
Sep-01-15Upgrade Morgan Stanley Underweight → Overweight
Jun-09-15Initiated Guggenheim Neutral
May-21-15Initiated Barclays Overweight $74
Jan-08-15Reiterated Mizuho Buy $72 → $81
Jul-31-14Reiterated Mizuho Buy $61 → $59
Apr-10-14Upgrade Mizuho Neutral → Buy $55 → $61
Apr-09-14Reiterated MKM Partners Sell $32 → $35
Feb-28-14Reiterated UBS Neutral $42 → $53
Feb-28-14Reiterated MKM Partners Sell $26 → $32
Feb-28-14Reiterated Mizuho Neutral $33 → $56
Dec-05-13Downgrade UBS Buy → Neutral $37 → $42
Nov-01-13Reiterated Mizuho Neutral $30 → $33
Dec-05-16 03:00PM  CERC: CERC-501 Not Successful in Nicotine Withdrawal; Preparing for Phase 2/3 Study of CERC-501 in MDD
Dec-02-16 04:31PM  ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers
Nov-30-16 12:30PM  CERC: CERC-301 Fails to Show Benefit in MDD in Phase 2 Clinical Trial; Attention Now Turns to CERC-501
Nov-22-16 08:53AM  Acorda Stops Post-Stroke Development Program on Ampyra
Nov-18-16 04:49PM  Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Points Bet on Healthcare Sector Paid Off? at Insider Monkey
Nov-15-16 03:44PM  Alkermes (ALKS) CEO Pops Says Biotech Stocks 'Recovered Quite a Bit' Post-Election
02:36PM  Drug pricing pressure
Nov-10-16 12:00PM  ETFs with exposure to Alkermes Plc : November 10, 2016
Nov-09-16 04:00PM  Alkermes Corporate Presentation to be Webcast at the Jefferies 2016 London Healthcare Conference Business Wire +7.73%
10:01AM  Alkermes Plc :ALKS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016
Nov-07-16 02:55PM  Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward at Motley Fool
Nov-05-16 01:04PM  ALKERMES PLC. Financials
Nov-03-16 09:00AM  Alkermes (ALKS) Q3 Loss in Line, Sales Miss; '16 View Intact
07:00AM  ALKERMES Inspiration Grants Awarded to Support People Affected by Mental Health and Substance Use Disorders Business Wire
Nov-02-16 01:41PM  Edited Transcript of ALKS earnings conference call or presentation 2-Nov-16 12:30pm GMT
08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today
07:32AM  Alkermes reports 3Q loss
07:08AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:07AM  Q3 2016 Alkermes Plc Earnings Release - Before Market Open
07:00AM  Alkermes plc Reports Third Quarter 2016 Financial Results Business Wire
Nov-01-16 04:00PM  Alkermes Corporate Presentation to be Webcast at the Credit Suisse 25th Annual Healthcare Conference Business Wire
08:20AM  Drug Stocks to Watch for Earnings on Nov 2; AGN, ZTS & More
Oct-27-16 06:00AM  Jim Cramer's Top Takeaways: Norfolk Southern, Apple, Snap-On
Oct-26-16 07:16PM  Cramer Remix: Who is right and wrong when it comes to Apple at CNBC
04:00PM  Alkermes to Host Conference Call to Discuss Third Quarter 2016 Financial Results Business Wire
09:43AM  Biotech Stock Roundup: Clinical Holds Hit Inovio & Aduro, Vertex Q3 Results Miss Estimates
Oct-25-16 10:10AM  Hot Tech and Biotech Companies Highlight Jefferies Stocks to Buy at 24/7 Wall St.
Oct-24-16 04:20PM  Alkermes, Lundbeck Cannibalize Johnson & Johnson's Schizophrenia Sales
09:59AM  What To Watch From The Upcoming Cerecor Inc (CERC) Release at Insider Monkey
09:30AM  Alkermes Depression Drug Shows Good Results (ALKS) at Investopedia
08:18AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : October 24, 2016
07:55AM  Are Alkermes Analysts Chasing This Story Too Hard, or Is It Just a Start? at 24/7 Wall St.
Oct-22-16 01:26PM  Reynolds American, Inc. (RAI), MGP Ingredients Inc (MGPI), and More: Heres What Analysts Had To Say About These Stocks in the Spotlight at Insider Monkey
Oct-21-16 06:45PM  [$$] Clinical Development News, Oct. 17-21 at The Wall Street Journal +27.83%
04:15PM  Alkermes stock surges on depression drug's success in late-stage trial at CNBC
04:09PM  Alkermes Hits 9-Month High On 'Blockbuster Potential' Antidepressant
02:30PM  Alkermes, Inc. -- Moody's Alkermes' FORWARD-5 trial is credit positive at Moody's
01:32PM  Why Alkermes PLC Skyrocketed Today at Motley Fool
12:52PM  Alkermes (ALKS) Stock Soars on Trial Results, Upgrades
09:25AM  Alkermes Depression Candidate Positive in Phase III Study
09:09AM  The Market In 5 Minutes: Big Earnings In Focus And A Tobacco Giant In The Making
09:07AM  Early movers: GE, HON, STI, COH, MSFT, RAI, AMD, SKX, SLB & more at CNBC
08:30AM  Why Traders Are Buzzing About Qualcomm, NXP, Alkermes, Cerecor, and More at Insider Monkey
07:45AM  Why Despite Alkermes Success, Suicidal Ideation Still Eludes Big Pharma at 24/7 Wall St.
07:07AM  Alkermes' depression drug trial win could be a test case for the FDA at bizjournals.com
06:04AM  Alkermes upgraded by JP Morgan
Oct-20-16 05:18PM  [$$] Alkermes Shares Surge at The Wall Street Journal
05:04PM  After-hours buzz: MSFT, ALKS, PYPL and more at CNBC
05:00PM  Alkermes Plc Conference Call to Discuss FORWARD-5 ALKS 5461 Data scheduled for 5:00 pm ET today
04:41PM  Alkermes Soars As Antidepressant Finally Delivers At Trials
04:25PM  Alkermes shares soar more than 40% after depression drug results at MarketWatch
04:24PM  Depression drug by Walthams Alkermes aces late-stage trial at bizjournals.com
04:15PM  Alkermes Surges as Depression Drug Hits Goal in Late-Stage Trial
04:15PM  Alkermes Surges as Depression Drug Hits Goal in Late Trial at Bloomberg
04:06PM  Alkermes Depression Drug Finds Success on Third Study Attempt
04:04PM  Alkermes releases positive data on depression data
04:03PM  ALKERMES PLC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
04:00PM  Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder Business Wire
Oct-13-16 04:51PM  ALKERMES PLC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Oct-04-16 06:16PM  Alkermes Commences Metabolic Study on Schizophrenia Drug
Oct-03-16 10:34AM  Recro Pharma Offers A Non-Opioid Alternative For Pain Management; Brean Assumes With Buy Rating
07:00AM  Alkermes Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for Treatment of Schizophrenia Business Wire
Sep-30-16 08:30AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : September 30, 2016
Sep-27-16 10:39AM  Jim Cramer -- Gilead Needs to Make an Acquisition
09:54AM  Cramer's Stop Trading: GILD, GWPH & ALKS
Sep-23-16 04:33PM  Virgin Extends Drop As Alaska Air Merger Review Grows Longer
Sep-20-16 04:14PM  ALKERMES PLC. Files SEC form 8-K/A, Change in Directors or Principal Officers
Sep-19-16 04:00PM  Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016 Business Wire
Sep-15-16 11:13AM  Moving Average Crossover Alert: Alkermes (ALKS)
Sep-12-16 07:00AM  Alkermes Launches Competitive Grants Program to Support People Affected by Mental Health and Substance Use Disorders Business Wire +5.20%
Sep-09-16 01:51PM  Alkermes Plc Value Analysis (NASDAQ:ALKS) : September 9, 2016
Sep-08-16 08:03AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : September 8, 2016
Sep-06-16 04:00PM  Alkermes Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Business Wire
Aug-25-16 10:00AM  ETFs with exposure to Alkermes Plc : August 25, 2016
Aug-24-16 08:03AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : August 24, 2016
Aug-15-16 10:00AM  Want a Dash for Trash? Why Not Look at Alkermes
Aug-11-16 08:14AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : August 11, 2016
Aug-08-16 07:00AM  Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA┬« for Treatment of Schizophrenia Business Wire
Aug-04-16 02:36PM  ETFs with exposure to Alkermes Plc : August 4, 2016
Aug-03-16 12:29PM  Alkermes Plc :ALKS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016
Jul-29-16 12:44PM  ALKERMES PLC. Files SEC form 8-K, Other Events
11:06AM  Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook
Jul-28-16 08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today -7.05%
08:20AM  Alkermes reports 2Q loss
07:07AM  Q2 2016 Alkermes Plc Earnings Release - Before Market Open
07:06AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:00AM  Alkermes plc Reports Second Quarter 2016 Financial Results Business Wire
Jul-27-16 03:00PM  A Look At Recro Pharma Inc (REPH) and Alkermes Plc (ALKS)s Topline Triumph at Insider Monkey
06:00AM  Jim Cramer's Top Takeaways: Acacia Communications, KeyCorp, Alkermes
Jul-26-16 07:09PM  Cramer Remix: It's time for Jack Dorsey to make a choice at CNBC
03:00PM  [$$] Three Biotech Q2 Reports Hold Potential at Barrons.com
Jul-22-16 07:53PM  Whats Been Beating down the Fidelity Growth Company Fund in 2016?
Jul-21-16 04:00PM  Alkermes to Host Conference Call to Discuss Second Quarter 2016 Financial Results Business Wire
Jun-21-16 11:21AM  Alkermes Plc Value Analysis (NASDAQ:ALKS) : June 21, 2016
Jun-20-16 08:38AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : June 20, 2016
Jun-08-16 04:19PM  ALKERMES PLC. Files SEC form 8-K, Other Events
02:10PM  ETFs with exposure to Alkermes Plc : June 8, 2016
Jun-02-16 04:11PM  ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers
Jun-01-16 04:06PM  Alkermes Rises on Evercores Buy Rating, Buying Support
04:00PM  Alkermes Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare Conference Business Wire
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company's marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; INVEGA TRINZA for the treatment of schizophrenia used in people who have been treated with INVEGA SUSTENNA; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to improve walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in a Phase III study for the treatment of major depressive disorder; ALKS 3831, which is in a Phase II study to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in a Phase I study to treat multiple sclerosis; ALKS 6428, which is in a phase III study to help physicians transition patients from physical dependence on opioids to antagonist therapy; Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I study for the treatment of schizophrenia; ALKS 7119 that is in a Phase I study for the treatment of various central nervous system diseases; RDB 1450, a proprietary investigational biologic cancer immunotherapy product that is in pre-clinical stage. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Janssen Pharmaceutica N.V.; AstraZeneca plc; and Acorda Therapeutics, Inc. Alkermes Public Limited Company was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSDec 01Option Exercise14.3815,000215,70053,687Dec 02 05:40 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSDec 01Sale56.1315,000841,98938,687Dec 02 05:40 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 30Option Exercise14.3810,000143,800165,659Nov 30 05:16 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 30Sale57.5110,000575,083155,659Nov 30 05:16 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 29Option Exercise14.3830,000431,400638,962Nov 30 05:14 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 29Sale56.9830,0001,709,469608,962Nov 30 05:14 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 22Option Exercise14.3830,000431,400638,962Nov 22 05:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 22Sale58.6630,0001,759,936608,962Nov 22 05:05 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSNov 18Option Exercise16.556,04299,99595,474Nov 21 06:02 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 16Option Exercise14.3810,000143,800165,659Nov 17 06:10 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 16Sale58.5910,000585,901155,659Nov 17 06:10 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 15Option Exercise14.3830,000431,400638,962Nov 17 06:07 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 15Sale58.8230,0001,764,525608,962Nov 17 06:07 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Nov 11Option Exercise13.883,44347,78624,957Nov 14 05:53 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncNov 10Option Exercise17.305,78099,99435,807Nov 14 05:49 PM
BREYER ROBERT ADirectorNov 10Sale60.0020,0001,200,00015,156Nov 14 05:46 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 09Option Exercise14.3810,000143,800165,659Nov 10 05:28 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 09Sale56.2210,000562,183155,659Nov 10 05:28 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 08Option Exercise14.3830,000431,400638,962Nov 10 05:18 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 08Sale53.2830,0001,598,462608,962Nov 10 05:18 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Nov 07Option Exercise11.748,51799,99056,475Nov 08 05:06 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncOct 05Option Exercise0.005,000031,650Oct 06 09:15 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Oct 05Option Exercise0.005,000022,803Oct 06 09:14 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Oct 05Option Exercise0.005,0000158,012Oct 06 09:09 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Oct 05Option Exercise0.001,600022,034Oct 06 09:07 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSOct 05Option Exercise0.005,000091,785Oct 06 09:04 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Oct 05Option Exercise0.005,000050,311Oct 06 09:01 PM
Cooke ShanePresident, Alkermes plcOct 05Option Exercise0.007,500067,844Oct 06 08:59 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Oct 05Option Exercise0.001,600023,827Oct 06 08:57 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSOct 05Option Exercise0.005,000041,540Oct 06 08:55 PM
POPS RICHARD FDirector and CEO, Alkermes plcOct 05Option Exercise0.0020,0000618,372Oct 07 04:02 PM
MITCHELL PAUL JDirectorOct 04Option Exercise18.292,00036,58010,000Oct 04 05:25 PM
MITCHELL PAUL JDirectorOct 04Sale47.422,00094,8408,000Oct 04 05:25 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 22Option Exercise18.113,83469,41549,145Sep 22 05:01 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 22Sale50.843,834194,92645,311Sep 22 05:01 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 21Option Exercise18.111,16621,11046,477Sep 22 05:01 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 21Sale50.811,16659,24245,311Sep 22 05:01 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 16Option Exercise18.115,00090,52550,311Sep 19 05:21 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 16Sale48.875,000244,33145,311Sep 19 05:21 PM
MITCHELL PAUL JDirectorSep 06Option Exercise18.292,00036,58010,000Sep 07 05:13 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Sep 06Option Exercise14.382,38234,25322,816Sep 07 05:16 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 06Option Exercise18.1110,000181,05055,311Sep 07 05:31 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Sep 06Sale45.9229,9761,376,62722,227Sep 07 05:27 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Sep 06Sale45.922,382109,37820,434Sep 07 05:16 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 06Sale46.0210,000460,23545,311Sep 07 05:31 PM
MITCHELL PAUL JDirectorSep 06Sale45.922,00091,8348,000Sep 07 05:13 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Aug 05Option Exercise16.556,04299,99517,803Aug 08 05:09 PM
MITCHELL PAUL JDirectorAug 04Option Exercise18.292,00036,58010,000Aug 05 05:04 PM
MITCHELL PAUL JDirectorAug 04Sale49.482,00098,9668,000Aug 05 05:04 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jul 27Option Exercise16.5534,399569,30379,710Jul 28 05:06 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jul 27Sale51.9534,3991,787,07645,311Jul 28 05:06 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jul 26Option Exercise16.5580013,24046,111Jul 28 05:06 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jul 26Sale51.8280041,45545,311Jul 28 05:06 PM
MITCHELL PAUL JDirectorJul 05Option Exercise18.292,00036,58010,000Jul 06 05:17 PM
MITCHELL PAUL JDirectorJul 05Sale45.812,00091,6208,000Jul 06 05:17 PM
MITCHELL PAUL JDirectorJun 06Option Exercise18.292,00036,58010,000Jun 07 05:33 PM
MITCHELL PAUL JDirectorJun 06Sale44.982,00089,9508,000Jun 07 05:33 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.May 28Option Exercise0.003,750047,076Jun 01 05:26 PM
Cooke ShanePresident, Alkermes plcMay 28Option Exercise0.005,750063,334Jun 01 05:23 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.May 28Option Exercise0.001,750052,771Jun 01 05:15 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSMay 28Option Exercise0.003,750038,305Jun 01 05:09 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 28Option Exercise0.001,250020,840Jun 01 06:19 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 28Option Exercise0.0013,7500598,372Jun 01 06:06 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 28Option Exercise0.002,5000153,012Jun 01 05:52 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMay 28Option Exercise0.002,500057,778Jun 01 05:35 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMay 28Option Exercise0.002,500026,650Jun 01 06:34 PM
BIBERSTEIN KATHRYN LEVP/CLO/CCO Alks Inc; Sec ALKSMay 21Option Exercise0.004,500036,076May 23 05:30 PM
Brown Iain MichaelVP Finance & CAO, Alkermes IncMay 21Option Exercise0.002,125051,711May 23 05:37 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.May 21Option Exercise0.004,500045,444May 23 05:46 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMay 21Option Exercise0.003,750056,537May 23 05:59 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.May 21Option Exercise0.004,125011,074May 23 06:17 PM
MITCHELL PAUL JDirectorMay 04Option Exercise18.292,00036,58010,000May 05 05:27 PM
MITCHELL PAUL JDirectorMay 04Sale38.602,00077,2008,000May 05 05:27 PM
Brown Iain MichaelVP Finance & CAO, Alkermes IncApr 22Option Exercise20.793,13265,11449,586Apr 25 05:26 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Apr 20Option Exercise20.7916,875350,831163,637Apr 20 05:19 PM
BIBERSTEIN KATHRYN LEVP/CLO/CCO Alks Inc; Sec ALKSApr 20Option Exercise20.7912,657263,13931,576Apr 20 05:34 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Apr 20Sale41.0916,875693,403146,762Apr 20 05:19 PM
POPS RICHARD FDirector and CEO, Alkermes plcApr 19Option Exercise20.7918,750389,813595,247Apr 20 05:16 PM
POPS RICHARD FDirector and CEO, Alkermes plcApr 19Sale40.1518,750752,863576,497Apr 20 05:16 PM
Brown Iain MichaelVP Finance & CAO, Alkermes IncApr 18Option Exercise20.795,368111,60151,822Apr 20 05:03 PM
Brown Iain MichaelVP Finance & CAO, Alkermes IncApr 18Sale39.275,368210,81646,454Apr 20 05:03 PM
POPS RICHARD FDirector and CEO, Alkermes plcApr 12Option Exercise20.7925,000519,750601,497Apr 13 05:15 PM
POPS RICHARD FDirector and CEO, Alkermes plcApr 12Sale37.7925,000944,839576,497Apr 13 05:15 PM
MITCHELL PAUL JDirectorApr 04Option Exercise18.292,00036,58010,000Apr 05 05:23 PM
MITCHELL PAUL JDirectorApr 04Sale35.652,00071,3008,000Apr 05 05:23 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 22Option Exercise20.7925,000519,750601,497Mar 23 05:10 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 22Sale31.7725,000794,353576,497Mar 23 05:10 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 15Option Exercise20.7925,000519,750601,497Mar 16 05:35 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 15Sale31.4025,000784,910576,497Mar 16 05:35 PM
MITCHELL PAUL JDirectorMar 04Option Exercise18.292,00036,58010,000Mar 04 05:38 PM
MITCHELL PAUL JDirectorMar 04Sale32.802,00065,6008,000Mar 04 05:38 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 03Option Exercise18.5526,128484,71952,787Mar 04 05:27 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 03Option Exercise0.002,8130146,762Mar 04 05:28 PM
Brown Iain MichaelVP Finance & CAO, Alkermes IncMar 03Option Exercise0.001,250046,860Mar 04 05:15 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Mar 03Option Exercise0.003,25008,004Mar 04 05:33 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 03Option Exercise0.0013,0000576,497Mar 04 05:29 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMar 03Option Exercise0.002,813024,150Mar 04 05:35 PM
ANSTICE DAVID WDirectorMar 03Buy32.875,000164,36615,000Mar 04 05:36 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 26Option Exercise0.0010,0000563,497Mar 01 05:45 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Feb 26Option Exercise0.003,750039,628Mar 01 05:31 PM